CANCER DISCOVERY CONTENTS

JUNE 2014 ▪ VOLUME 4 ▪ NUMBER 6

IN THIS ISSUE
Highlighted research articles 621

NEWS IN BRIEF
Important news stories affecting the community 624

NEWS IN DEPTH
Q&A: Brian Kennedy on Aging and Cancer 627

New Nanomedicines May Better Target Tumors 628

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature 629

ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

IN THE SPOTLIGHT
Second-Generation ALK Inhibitors: Filling the Non-MET Gap 634
S.S. Ramalingam and F.R. Khuri
See article, p. 662

Soil Amendments That Slow Cancer Growth 637
C.M. Isacke and M.H. Barcellos-Hoff
See article, p. 716

VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib 640
X. Luo and G.-S. Feng
See article, p. 730

EML4–ALK Fusions: Propelling Cancer but Creating Exploitable Chaperone Dependence 642
P. Workman and R. van Montfort

IN FOCUS
Surviving Metabolic Stress: Of Mice (Squirrels) and Men 646
W.N. Hait, M. Versele, and J.-M. Yang

REVIEW
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA 650
D.A. Haber and V.E. Velculescu

RESEARCH ARTICLES
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer 662
Précis: Ceritinib, a next-generation ALK inhibitor, has potent activity in preclinical models of crizotinib-naïve and crizotinib-resistant ALK-rearranged non–small cell lung cancer.
See commentary, p. 634

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation 674
Précis: Type I IFN–associated inflammatory pathway activation combined with antibody blockade of the T-cell immunoinhibitory receptor PD-1 improves immune surveillance of melanomas.

Inflammation-Induced NFATc1–STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by KrasG12D 688
Précis: Type I IFN–associated inflammatory pathway activation combined with antibody blockade of the T-cell immunoinhibitory receptor PD-1 improves immune surveillance of melanomas.

VEGFA Genomic Amplification Tailors Treatment of HCCs with Sorafenib 640
X. Luo and G.-S. Feng
See article, p. 730

EML4–ALK Fusions: Propelling Cancer but Creating Exploitable Chaperone Dependence 642
P. Workman and R. van Montfort

In Focus
Surviving Metabolic Stress: Of Mice (Squirrels) and Men 646
W.N. Hait, M. Versele, and J.-M. Yang

Downloaded from cancerdiscovery.aacrjournals.org on June 29, 2017. © 2014 American Association for Cancer Research.
Friboulet and colleagues report that ceritinib, a next-generation ALK inhibitor that is more selective and potent than crizotinib, is active in preclinical models of both crizotinib-naïve and crizotinib-resistant non-small cell lung cancer (NSCLC). Ceritinib retained activity against the most common crizotinib-resistant ALK mutants, although some secondary ALK mutations did confer resistance to both crizotinib and ceritinib. Structural analyses provided a mechanistic basis for these findings, as the most common secondary ALK mutations that inhibit binding of crizotinib are not predicted to impair ceritinib binding, but other mutations, which the authors have identified in patients with acquired resistance to ceritinib, are predicted to reduce ceritinib binding through steric hindrance or conformational changes of the ALK catalytic domain. For details, please see the article by Friboulet and colleagues on page 662.